Drug intelligence / Profile preview

KP23901

Development stage: Preclinical
Lead developer: Korea Pharma

Overview

**KP23901** is a Korea Pharma preclinical drug candidate being developed for improvement of menopausal and postmenopausal symptoms. Korea Pharma's public research pipeline identifies the program and its preclinical status, but does not publicly disclose its chemical identity, modality, molecular target, mechanism of action, formulation, dosage form, or route of administration. ([koreapharma.co.kr](https://koreapharma.co.kr/eng/sub_research/result.php))

Beyond the preview

Go deeper on KP23901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP23901.

Explore the full profile